Neosync ranked #30 Holder of Pervasive Neurotech Intellectual Property*

Neo­sync is an ear­ly stage com­pa­ny devel­op­ing a new treat­ment  for major depres­sion based on Tran­scra­nial Mag­net­ic Stim­u­la­tion (TMS). The treatment–named NEST (Neo­sync EEG Syn­chro­nized TMS) and under­go­ing clin­i­cal trials–is based on the idea that depres­sion patients tend to have over­ly rhyth­mic brain activity, 

Read More